0000000000668348

AUTHOR

Kathy Vander Eeckt

showing 3 related works from this author

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT

2017

Bladder cancer BCG T1HG re-TURSettore MED/24 - Urologia
researchProduct

RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER

2017

Bladder cancer T1HG re-TUR BCGSettore MED/24 - Urologia
researchProduct